DK2917210T3 - Alk kinase-inhibitorer - Google Patents
Alk kinase-inhibitorer Download PDFInfo
- Publication number
- DK2917210T3 DK2917210T3 DK13853072.0T DK13853072T DK2917210T3 DK 2917210 T3 DK2917210 T3 DK 2917210T3 DK 13853072 T DK13853072 T DK 13853072T DK 2917210 T3 DK2917210 T3 DK 2917210T3
- Authority
- DK
- Denmark
- Prior art keywords
- kinase inhibitors
- alk kinase
- alk
- inhibitors
- kinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261723099P | 2012-11-06 | 2012-11-06 | |
| PCT/CN2013/086571 WO2014071832A1 (en) | 2012-11-06 | 2013-11-05 | Alk kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2917210T3 true DK2917210T3 (da) | 2019-05-27 |
Family
ID=50622903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13853072.0T DK2917210T3 (da) | 2012-11-06 | 2013-11-05 | Alk kinase-inhibitorer |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9206166B2 (da) |
| EP (1) | EP2917210B1 (da) |
| JP (2) | JP6359020B6 (da) |
| KR (1) | KR102156398B1 (da) |
| CN (1) | CN104854101B (da) |
| AU (1) | AU2013344049B2 (da) |
| BR (1) | BR112015010221B1 (da) |
| CA (1) | CA2890006C (da) |
| DK (1) | DK2917210T3 (da) |
| ES (1) | ES2728008T3 (da) |
| RU (1) | RU2675850C2 (da) |
| WO (1) | WO2014071832A1 (da) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014071832A1 (en) * | 2012-11-06 | 2014-05-15 | Shanghai Fochon Pharmaceutical Co Ltd | Alk kinase inhibitors |
| CN105085550B (zh) * | 2014-05-21 | 2017-05-24 | 海门慧聚药业有限公司 | 一类alk激酶抑制剂及其制备方法 |
| CN105272921A (zh) * | 2014-06-09 | 2016-01-27 | 江苏奥赛康药业股份有限公司 | 一种制备Ceritinib的方法及其中间体化合物 |
| CN105622520A (zh) * | 2014-08-25 | 2016-06-01 | 上海博悦生物科技有限公司 | 一种治疗非小细胞肺癌药物色瑞替尼(Ceritinib)的新中间体及其制备方法 |
| EP3191097B1 (en) * | 2014-09-13 | 2019-10-23 | Novartis AG | Combination therapies |
| EP3202765B1 (en) * | 2014-09-29 | 2020-03-25 | Hainan Xuanzhu Pharma Co., Ltd. | Polycyclic anaplastic lymphoma kinase inhibitor |
| CN106146525B (zh) * | 2015-04-10 | 2018-11-02 | 山东轩竹医药科技有限公司 | 三并环类间变性淋巴瘤激酶抑制剂 |
| CN106146478B (zh) * | 2015-04-10 | 2019-07-16 | 海南轩竹医药科技有限公司 | 三嗪衍生物类间变性淋巴瘤激酶抑制剂 |
| CN104892526A (zh) * | 2015-06-17 | 2015-09-09 | 药源药物化学（上海）有限公司 | 一种2,5-二氯-n-(2-(异丙基磺酰基)苯基)嘧啶-4-胺的制备方法 |
| CN106699810A (zh) * | 2015-11-17 | 2017-05-24 | 清华大学 | 一种含氮杂环化合物及其制备方法与在抑制激酶活性中的应用 |
| CN109071512A (zh) * | 2016-02-03 | 2018-12-21 | 重庆复创医药研究有限公司 | 作为激酶抑制剂的含磷化合物 |
| US10710993B2 (en) * | 2016-06-27 | 2020-07-14 | Hangzhou REX Pharmaceutical Co., LTD. | Benzofuran pyrazole amine kinase inhibitor |
| CN108276410B (zh) * | 2017-01-06 | 2021-12-10 | 首药控股(北京)股份有限公司 | 一种间变性淋巴瘤激酶抑制剂及其制备方法和用途 |
| TWI798334B (zh) | 2018-01-31 | 2023-04-11 | 大陸商迪哲（江蘇）醫藥股份有限公司 | Ｅｒｂｂ／ｂｔｋ抑制劑 |
| JP7322140B6 (ja) * | 2018-05-02 | 2024-02-21 | ジェイダブリュ ファーマシューティカル コーポレーション | 新規なヘテロサイクル誘導体 |
| US20210260124A1 (en) | 2018-06-22 | 2021-08-26 | Junten Bio Co., Ltd. | Antibody capable of inducing immune tolerance produced using cell mixture having complexed state, and induced lymphocyte or cell therapeutic agent and cell therapy method each using induced lymphocyte |
| JPWO2019245039A1 (ja) | 2018-06-22 | 2021-06-24 | 株式会社Ｊｕｎｔｅｎ Ｂｉｏ | 感染性免疫寛容を惹起するための組成物 |
| CN110305140B (zh) * | 2019-07-30 | 2020-08-04 | 上海勋和医药科技有限公司 | 二氢吡咯并嘧啶类选择性jak2抑制剂 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0319227D0 (en) * | 2003-08-15 | 2003-09-17 | Novartis Ag | Organic compounds |
| GB0305929D0 (en) * | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| RU2400477C2 (ru) * | 2003-03-14 | 2010-09-27 | Новартис Аг | 2,4-ди(фениламино)пиримидины, применимые при лечении неопластических заболеваний, воспалительных нарушений и нарушений иммунной системы |
| NZ585188A (en) * | 2003-08-15 | 2011-09-30 | Novartis Ag | 2,4-Pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
| EP1713806B1 (en) * | 2004-02-14 | 2013-05-08 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| GB0419161D0 (en) * | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
| KR101026676B1 (ko) * | 2005-12-05 | 2011-04-04 | 화이자 프로덕츠 인코포레이티드 | 비정상 세포 성장의 치료 방법 |
| TW200736232A (en) * | 2006-01-26 | 2007-10-01 | Astrazeneca Ab | Pyrimidine derivatives |
| US20080033412A1 (en) * | 2006-08-01 | 2008-02-07 | Harry Thomas Whelan | System and method for convergent light therapy having controllable dosimetry |
| WO2008051547A1 (en) * | 2006-10-23 | 2008-05-02 | Cephalon, Inc. | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors |
| KR101149295B1 (ko) | 2006-12-08 | 2012-07-05 | 아이알엠 엘엘씨 | 단백질 키나제 억제제로서의 화합물 |
| CN101616895A (zh) * | 2006-12-08 | 2009-12-30 | Irm责任有限公司 | 作为蛋白激酶抑制剂的化合物和组合物 |
| TWI389893B (zh) * | 2007-07-06 | 2013-03-21 | Astellas Pharma Inc | 二（芳胺基）芳基化合物 |
| BRPI0814777A2 (pt) * | 2007-08-08 | 2015-03-03 | Glaxosmithkline Llc | Composto, composição farmacêutica, método para tratar um neoplasma, uso de um composto, e, composição farmacêutica. |
| WO2009032694A1 (en) | 2007-08-28 | 2009-03-12 | Dana Farber Cancer Institute | Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis |
| US8440681B2 (en) * | 2007-08-28 | 2013-05-14 | Irm Llc | 2-biphenylamino-4-aminopyrimidine derivatives as kinase inhibitors |
| TW200942537A (en) | 2008-02-01 | 2009-10-16 | Irm Llc | Compounds and compositions as kinase inhibitors |
| CA2720946C (en) * | 2008-04-07 | 2013-05-28 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| MX2010011069A (es) | 2008-04-07 | 2010-11-12 | Irm Llc | Compuestos y composiciones como inhibidores de cinasa. |
| CN102056927B (zh) | 2008-05-13 | 2014-06-25 | Irm责任有限公司 | 作为激酶抑制剂的稠合含氮杂环及其组合物 |
| SI2300013T1 (en) * | 2008-05-21 | 2018-03-30 | Adriad Pharmacaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| PE20100087A1 (es) | 2008-06-25 | 2010-02-08 | Irm Llc | Compuestos y composiciones como inhibidores de cinasa |
| MX2010014568A (es) | 2008-06-25 | 2011-03-29 | Irm Llc | Derivados de pirmidina como inhibidores de cinasa. |
| WO2010128659A1 (ja) * | 2009-05-08 | 2010-11-11 | アステラス製薬株式会社 | ジアミノへテロ環カルボキサミド化合物 |
| US8722692B2 (en) | 2009-07-30 | 2014-05-13 | Jianwei Che | Compounds and compositions as Syk kinase inhibitors |
| US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
| AU2010283806A1 (en) | 2009-08-12 | 2012-03-01 | Novartis Ag | Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation |
| JP5775871B2 (ja) | 2009-08-20 | 2015-09-09 | ノバルティス アーゲー | ヘテロ環式オキシム化合物 |
| IN2012DN02139A (da) | 2009-09-10 | 2015-08-07 | Novartis Ag | |
| MY177742A (en) | 2010-12-17 | 2020-09-23 | Novartis Ag | Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine |
| BR112013019643B1 (pt) | 2011-02-02 | 2022-04-19 | Novartis Ag | Uso de inibidores de álcali |
| WO2014071832A1 (en) * | 2012-11-06 | 2014-05-15 | Shanghai Fochon Pharmaceutical Co Ltd | Alk kinase inhibitors |
-
2013
- 2013-11-05 WO PCT/CN2013/086571 patent/WO2014071832A1/en active Application Filing
- 2013-11-05 CA CA2890006A patent/CA2890006C/en active Active
- 2013-11-05 AU AU2013344049A patent/AU2013344049B2/en active Active
- 2013-11-05 CN CN201380058088.6A patent/CN104854101B/zh active Active
- 2013-11-05 US US14/071,953 patent/US9206166B2/en not_active Expired - Fee Related
- 2013-11-05 EP EP13853072.0A patent/EP2917210B1/en active Active
- 2013-11-05 KR KR1020157014984A patent/KR102156398B1/ko active IP Right Grant
- 2013-11-05 ES ES13853072T patent/ES2728008T3/es active Active
- 2013-11-05 BR BR112015010221-2A patent/BR112015010221B1/pt active IP Right Grant
- 2013-11-05 RU RU2015121374A patent/RU2675850C2/ru active
- 2013-11-05 DK DK13853072.0T patent/DK2917210T3/da active
- 2013-11-05 JP JP2015540039A patent/JP6359020B6/ja active Active
-
2015
- 2015-10-29 US US14/926,729 patent/US9567342B2/en not_active Expired - Fee Related
-
2018
- 2018-04-10 JP JP2018075512A patent/JP6570001B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2728008T3 (es) | 2019-10-21 |
| JP6359020B6 (ja) | 2018-08-15 |
| JP6359020B2 (ja) | 2018-07-18 |
| BR112015010221A2 (pt) | 2017-07-11 |
| EP2917210A4 (en) | 2016-05-25 |
| CA2890006C (en) | 2021-11-23 |
| EP2917210A1 (en) | 2015-09-16 |
| WO2014071832A1 (en) | 2014-05-15 |
| JP6570001B2 (ja) | 2019-09-04 |
| JP2018119003A (ja) | 2018-08-02 |
| US9567342B2 (en) | 2017-02-14 |
| AU2013344049A1 (en) | 2015-07-02 |
| RU2675850C2 (ru) | 2018-12-25 |
| KR102156398B1 (ko) | 2020-09-15 |
| US20140128387A1 (en) | 2014-05-08 |
| CA2890006A1 (en) | 2014-05-15 |
| RU2015121374A (ru) | 2016-12-27 |
| KR20150093687A (ko) | 2015-08-18 |
| CN104854101A (zh) | 2015-08-19 |
| EP2917210B1 (en) | 2019-02-27 |
| US9206166B2 (en) | 2015-12-08 |
| CN104854101B (zh) | 2018-05-01 |
| US20160046638A1 (en) | 2016-02-18 |
| BR112015010221B1 (pt) | 2022-09-13 |
| JP2015535266A (ja) | 2015-12-10 |
| AU2013344049B2 (en) | 2017-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2917210T3 (da) | Alk kinase-inhibitorer | |
| DK2903618T3 (da) | Rho-kinase-inhibitorer | |
| CO6970602A2 (es) | Inhibidores de quinasa | |
| HK1210775A1 (en) | Imidazotriazinecarbonitriles useful as kinase inhibitors | |
| DK2710007T3 (da) | Kinasehæmmere | |
| DK2895484T3 (da) | Glucosylceramidsynthase-inhibitorer | |
| DK3321262T3 (da) | Serin-/threoninkinasehæmmere | |
| HK1208442A1 (en) | Substituted pyrrolopyrimidinylamino-benzothiazolones as mknk kinase inhibitors mknk | |
| SMT201600114B (it) | Inibitori di beta-secretasi | |
| HK1215577A1 (zh) | 蛋白激酶抑制劑 | |
| DK2841428T3 (da) | Dna-pk-inhibitorer | |
| DK3181567T3 (da) | Pyrazolopyrimidinforbindelser som kinasehæmmere | |
| CO6950481A2 (es) | Inhibidores de proteínas quinasas | |
| DK3527563T3 (da) | Dna-pk-inhibitorer | |
| HK1211578A1 (en) | Amidoimidazopyridazines as mknk-1 kinase inhibitors mknk-1 | |
| CO6880068A2 (es) | Aminoquinazolinas como inhibidores de quinasa | |
| HK1209726A1 (en) | Protein kinase inhibitors | |
| HK1205507A1 (en) | Protein kinase inhibitors | |
| CO6990735A2 (es) | Inhibidores de pirazina cinasa | |
| BR112015005361A2 (pt) | inibidores de tirosina quinase de bruton | |
| SG11201500973WA (en) | Amino-quinolines as kinase inhibitors | |
| SMT201600357B (it) | Inibitori di iap | |
| HK1208460A1 (en) | Protein kinase inhibitors | |
| EP2968358A4 (en) | NOVEL CHOLINKINASE INHIBITORS | |
| HK1222848A1 (zh) | 用作 抑制劑的吡咯並三嗪 |